UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 27

Sortiert nach

Reevaluating Eligibility Criteria — Balancing Patient Protection and Participation in Oncology Trials

The New England journal of medicine, 2017-04, Vol.376 (16), p.1504-1505

2017

Link zum Volltext

Verfügbarkeit prüfen

Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement

Journal of clinical oncology, 2017-11, Vol.35 (33), p.3737-3744

2017

Link zum Volltext

Verfügbarkeit prüfen

Impact of broadening clinical trial eligibility criteria for advanced non-small cell lung cancer patients: Real-world analysis

Journal of clinical oncology, 2019-06, Vol.37 (18_suppl), p.LBA108-LBA108

2019

Link zum Volltext

Verfügbarkeit prüfen

Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients

Journal of clinical oncology, 2022-10, Vol.40 (30), p.3489-3500

2022

Link zum Volltext

Verfügbarkeit prüfen

FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy

Clinical cancer research, 2015-10, Vol.21 (19), p.4257-4261

2015

Link zum Volltext

Verfügbarkeit prüfen

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research HIV Working Group

Journal of clinical oncology, 2017-11, Vol.35 (33), p.3774-3780

2017

Link zum Volltext

Verfügbarkeit prüfen

Broadening Eligibility Criteria for Oncology Clinical Trials: Current Advances and Future Directions

Clinical pharmacology and therapeutics, 2020-09, Vol.108 (3), p.419-421

2020

Link zum Volltext

Verfügbarkeit prüfen

U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review

Clinical cancer research, 2022-03, Vol.28 (6), p.1072-1086

2022

Link zum Volltext

Verfügbarkeit prüfen

Updated FDA pooled analysis of pain medication use in trial participants with HR+, HER2-negative metastatic breast cancer treated with endocrine therapy and a CDK 4/6 inhibitor

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e24101-e24101

2022

Link zum Volltext

Verfügbarkeit prüfen

Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO-Friends of Cancer Research Joint Research Statement

Clinical cancer research, 2021-05, Vol.27 (9), p.2394-2399

2021

Link zum Volltext

Verfügbarkeit prüfen

Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non-Small Cell Lung Cancer: Real-World Analysis of Select ASCO- Friends Recommendations

Clinical cancer research, 2021-05, Vol.27 (9), p.2430-2434

2021

Link zum Volltext

Verfügbarkeit prüfen

Enrollment representation of age, race, and ethnicity in ovarian cancer registrational clinical trials (2010-2020): An evaluation by the U.S. Food and Drug Administration

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e18527-e18527

2023

Link zum Volltext

Verfügbarkeit prüfen

Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis

The lancet oncology, 2021-11, Vol.22 (11), p.1573-1581

2021

Link zum Volltext

Verfügbarkeit prüfen

FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer

Clinical cancer research, 2023-10, Vol.29 (19), p.3835

2023

Link zum Volltext

Verfügbarkeit prüfen

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Prior Therapies Work Group

Clinical cancer research, 2021-05, Vol.27 (9), p.2408-2415

2021

Link zum Volltext

Verfügbarkeit prüfen

Pain medication use in patients with HR+, HER2-neg advanced breast cancer treated with endocrine therapy and a CDK 4/6 inhibitor: A U.S. FDA pooled analysis

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e24145-e24145

2020

Link zum Volltext

Verfügbarkeit prüfen

U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in Review

Clinical cancer research, 2022-03, Vol.28 (6), p.1058-1071

2022

Link zum Volltext

Verfügbarkeit prüfen

Overall survival in patients with breast cancer treated with a CDK 4/6 inhibitor plus fulvestrant: A U.S. Food and Drug Administration pooled analysis

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.1055-1055

2021

Link zum Volltext

Verfügbarkeit prüfen

FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs

Clinical cancer research, 2016-09, Vol.22 (18), p.4545-4549

2016

Link zum Volltext

Verfügbarkeit prüfen

Causes of patient ineligibility in clinical trials of metastatic urothelial cancer

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.4556-4556

2019

Link zum Volltext

Verfügbarkeit prüfen

FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper

Gynecologic oncology, 2017-10, Vol.147 (1), p.3-10

2017

Link zum Volltext

Verfügbarkeit prüfen

Patient-reported pain and pain medication impact in patients with HR+ Her2-neg advanced breast cancer: A U.S. FDA pooled analysis

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e13027-e13027

2020

Link zum Volltext

Verfügbarkeit prüfen

Successes and Challenges of PARP Inhibitors in Cancer Therapy

Frontiers in oncology, 2015-10, Vol.5, p.222-222

2015

Link zum Volltext

Verfügbarkeit prüfen

Making Lung Cancer Clinical Trials More Inclusive: Recommendations for Expanding Eligibility Criteria

Journal of thoracic oncology, 2018-06, Vol.13 (6), p.748-751

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(27)

Sprache

Englisch
(27)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(20)
Science & Technology
(20)
Oncology
(18)
Humans
(14)
Female
(7)
United States
(7)
Clinical Trials As Topic - Methods
(5)
United States Food And Drug Administration
(5)
Antineoplastic Agents - Therapeutic Use
(4)
Clinical Trials As Topic
(4)
Clinical Trials As Topic - Standards
(4)
Drug Approval
(4)
Research Design
(4)
Adult
(3)
Biomedical Research
(3)
Treatment Outcome
(3)
Aged
(2)
Animals
(2)
Antineoplastic Agents - Pharmacology
(2)
Care And Treatment
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Reevaluating Eligibility Criteria — Balancing Patient Protection and Participation in Oncology Trials

Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement

Impact of broadening clinical trial eligibility criteria for advanced non-small cell lung cancer patients: Real-world analysis

Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients

FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research HIV Working Group

Broadening Eligibility Criteria for Oncology Clinical Trials: Current Advances and Future Directions

U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review

Updated FDA pooled analysis of pain medication use in trial participants with HR+, HER2-negative metastatic breast cancer treated with endocrine therapy and a CDK 4/6 inhibitor

Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO-Friends of Cancer Research Joint Research Statement

FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy

Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non-Small Cell Lung Cancer: Real-World Analysis of Select ASCO- Friends Recommendations

Enrollment representation of age, race, and ethnicity in ovarian cancer registrational clinical trials (2010-2020): An evaluation by the U.S. Food and Drug Administration

Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis

FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Prior Therapies Work Group

Pain medication use in patients with HR+, HER2-neg advanced breast cancer treated with endocrine therapy and a CDK 4/6 inhibitor: A U.S. FDA pooled analysis

U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in Review

Overall survival in patients with breast cancer treated with a CDK 4/6 inhibitor plus fulvestrant: A U.S. Food and Drug Administration pooled analysis

FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs

Causes of patient ineligibility in clinical trials of metastatic urothelial cancer

FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper

Patient-reported pain and pain medication impact in patients with HR+ Her2-neg advanced breast cancer: A U.S. FDA pooled analysis

Successes and Challenges of PARP Inhibitors in Cancer Therapy

Making Lung Cancer Clinical Trials More Inclusive: Recommendations for Expanding Eligibility Criteria

Suchergebnisse filtern